# Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients

> **NCT05528354** · EARLY_PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 58 (estimated)

## Conditions studied

- Hematopoietic Stem Cell Transplantation
- TP53

## Interventions

- **DRUG:** VEN and DEC based conditioning regimen
- **DRUG:** DEC

## Key facts

- **NCT ID:** NCT05528354
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-02
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2022-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05528354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05528354, "Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05528354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*